公开(公告)号：US20240247076A1

公开(公告)日：2024-07-25

申请号：US18014318

申请日：2021-07-02

Applicant: SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting XU ,  Xiaoxiao WANG ,  Yuhao JIN ,  Kangping GUO ,  Ling WANG ,  Minjie PANG ,  Pilin WANG

IPC: C07K16/36 ,  A61P7/02 ,  A61K39/00

CPC classification number: C07K16/36 ,  A61P7/02 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/90

Abstract: The present invention relates to the pharmaceutical and biological field, and discloses a single-domain antibody against coagulation factor XI (FXI) and derived protein thereof. In particular, the present invention discloses a coagulation factor XI (FXI) binding protein derived from a single-domain antibody against coagulation factor XI (FXI) and use thereof.

公开(公告)号：US20240076345A1

公开(公告)日：2024-03-07

申请号：US18270097

申请日：2021-12-27

Applicant: SUZHOU ALPHAMAB CO., LTD

Inventor： Ting XU ,  Yuhao JIN ,  Xiaoxiao WANG ,  Pilin WANG ,  Qian LI

IPC: C07K14/605 ,  A61K38/26 ,  A61P3/10

CPC classification number: C07K14/605 ,  A61K38/26 ,  A61P3/10 ,  C07K2319/30

Abstract: A human GLP-1 polypeptide variant, and a fusion protein or an immunoconjugate constructed by means of using the human GLP-1 polypeptide variant can be used for preventing, and/or treating metabolic diseases or conditions related to GLP-1.

公开(公告)号：US20190352404A1

公开(公告)日：2019-11-21

申请号：US16479858

申请日：2018-01-23

Applicant: SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting XU ,  Aiwu ZHOU ,  Yuhao JIN ,  Ling WANG ,  Jie WU ,  Hongqin HU ,  Xiaoxiao WANG

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/577 ,  G01N33/68 ,  C12N15/85

Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KNO35 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.